OMAR GREEN, PH.D.
CEO and Co-Founder
Dr. Green is formally trained as a chemist, which has provided the necessary scientific background to contribute to a diverse group of projects. He has applied his chemical expertise to spectroscopic and materials research. From 2010-2013, Dr. Green served as Lead Chemist with Agave BioSystems, in Ithaca, NY. In this capacity, his research proposals garnered $2.4 mil in funding. He has continued building on this track record at Ionica, which has garnered $250,000 in Phase I funding in its first 9 months of existence.
His experience in spectroscopy has allowed him to design a novel method for the detection of trihalomethanes (THMs) that does not require the use of caustic materials, or the heating of organic solvents. This Phase II effort was selected as a “Success Story” by the Air Force. Dr. Green has served as lead on multiple other Phase I projects for the Department of Defense SBIR, including: development of DNA-based nanoparticles for use as anti-sense “modular medicines” capable of being tailored to the needs of specific patients (Phase I & II), development of nanoparticles for transdermal detection of chemical warfare agents (Phase I & II), and development of metal containing polymers for luminescent detection of VOCs (Phase I).
Dr. Green received his Hon. B.Sc. from the University of Toronto with distinction in 1999 before receiving his Ph. D. in chemistry from the University of Wisconsin-Madison in 2005, where he worked with Professor J. N. Burstyn on the design and investigation of small molecule sensors using luminescent transition metal-based methods. He then completed two year postdoctoral stints at the California Institute of Technology (Caltech; 2006-2007) and Argonne National Laboratory (ANL; 2007-2009). At Caltech, Dr. Green investigated DNA/protein interactions using electrochemical methods. While at ANL, he joined the biomaterials group, which focused on the investigation of self-assembly of ionic liquids for application as supports for biomolecules.
Dr. Green has published five peer reviewed papers, including a review of polymerized ionic liquids, has been issued two patents, and has presented at multiple professional meetings, and has garnered over $2.5 million in SBIR/STTR funding over the last 3 years.
JOEL TABB, PH.D.
President and Co-Founder
Dr. Joel Tabb is President of Ionica Sciences. Since obtaining his Ph. D. in Biological Chemistry from The University of Michigan in 1989, he has worked in a variety of fields with the areas of biochemistry and biotechnology. From 1999-2013, Dr. Tabb served as Principal Scientist with Agave BioSystems, in Ithaca, NY. In his capacity as Principal Scientist, he was directly involved in the procurement of over 25 SBIR Phase I and 15 Phase II awards, resulting in greater than $12 million in funding.Many of the research programs that Joel led involved adapting fluorescent technologies to develop novel detection and biosensor systems.
Joel has lead two projects to develop isothermal DNA amplification based platforms to detect Coxiella burnetii, the causative agent for Q Fever, and Dengue virus in human blood samples. Additionally, he lead efforts to develop fluid-based, multiplexed, microsphere immunoassays using the Luminex xMAP system as a platform. A multiplexed, microsphere based suite of assays for detecting human serum antibodies to Hepatitis C Virus (HCV), Human T-Cell Leukemia Virus, Type I (HTLV-I), and Tuberculosis. He has also lead a project, in collaboration with Luminex Technologies, to develop novel microsphere based assays for detecting exposure in animals to agriculturally important pathogens. Other projects led by Dr. Tabb include: development of antibody-based fluorescent bioprobes for the detection of explosive agents; the development of novel fluorogenic biosensor using living immune cells as a signal transducer; development of a modular, microfluidic and microscope mounted flow cytometry system; quantum dot-based assay for flow cytometry; and the development of encapsulated fluorescent bioprobes for the in situ and stand-off detection of explosive agents.
In addition to holding a Ph.D. in Biological Chemistry from the University of Michigan (1989), Joel also earned a B.A. in Biochemistry from Brandeis University (1983).
Chief Business Officer
Mr. Koch is an accomplished and versatile senior executive in life sciences with a proven record of leadership and results. His operating experience includes global product strategy and marketing, product development, regulatory strategy, quality systems, patents, and clinical studies. Demonstrated success in startup capital with nearly $20 million from non-dilutive and government programs, seed funds, angel investors, foundations, venture debt and venture capital. Was Director of the sales organization at startup and VP of Marketing at exit for Adeza Biomedical. Developing a new market for a preterm birth diagnostic test (fFN), Adeza went public in 2004 and sold to Cytyc for $452M in 2007. Mr. Koch is a skilled communicator, adept at communicating vision and mission, attracting top tier talent, developing opinion leaders, and nurturing strategic relationships.
Mr. Koch graduated from Indiana University of Pennsylvania with a B.S. in Business Administration (1986)